Nucletron separates from Delft; looks towards half-billion-dollar mark
This article was originally published in Clinica
Executive Summary
Radiation oncology specialist Nucletron has targeted a three-fold increase in revenue within the next five years, following its recent successful spin-off from parent company Delft Instruments. Over the last few years, Delft has been selling many of its non-core subsidiaries in an attempt to focus on the oil and gas industry. This led to Nucletron proposing a management buy-out. The separation, which took effect from July 1, provides Nucletron with its own share capital and allows the company to progress towards a proposed employee-wide shareholding. Nucletron recorded sales of E120m ($165m) in 2006, but since becoming an independent player situated in the top four radiotherapy companies worldwide, the Dutch firm believes it can close the gap on the top three radiotherapy oncology giants Siemens, Elekta and Varian Medical Systems.